Bringing high-quality generic medicines to patients around the world
At Towa International, we work to research, develop, manufacture and distribute generic medicines to patients around the world, with the aim of contributing to improving people’s health.
Our
Ikigai
We contribute to people’s health
We are dedicated to people’s genuine smiles
Our
Activity
We research, develop, manufacture and distribute generic medicines
and value-added medicines for patients around the world.
1st and only Japanese
generics company with a direct presence in both Europe and the US
€0M+
in sales
0+
employees
0%+
of revenues invested in R&D
0
countries with direct presence
About
Us
Our journey begins in 1951 when Towa Pharmaceutical was founded in Osaka, a pharmaceutical company that specializes in the manufacture of therapeutic solutions in Japan.
In 2020 Towa Pharmaceutical became international by adding Towa International business, and we became its major company who operates worldwide within a platform of an R&D center, innovative production capabilities, and direct commercial presence in Europe and the United States of America.
We are building a global business to provide patients around the world with high-quality and high added– value medicines and to support the sustainability of health systems.
Our story together
TOWA
PHARMACEUTICAL
TOWA
INTERNATIONAL
1951
Towa Pharmaceutical was originally founded as a family-run business
1989
Pensa originates from PPI expertise and a non-infringement formulation of Omeprazole
1992
Contruction of Martorelles (Barcelona) manufacturing and R&D facilities
1998
Osaka Research Center and Osaka Distribution Center are constructed at Osaka, Japan
2004
Towa was listed on Tokio’s stock exchange.
2022
Internationalization process entering South America and Middle East though licenses and strategic alliances.
International
presence
Our business
Breckenridge Pharmaceutical.
The US.
Breckenridge markets and distributes branded, high-quality, cost-effective generic pharmaceuticals in the United States, under an own-label distribution model.
We act as a trusted pharmaceutical partner, offering our development and manufacturing partners a unique opportunity to reach the US market.
Towa Pharmaceutical Spain, Italy and Portugal.
Europe.
In 2022, we changed the name of our three commercial affiliates, being now: Towa Pharmaceutical.
We are still operating with our commercial brands, Pensa and ToLife, and planning to do a voluntary and slow transition for the benefit of our patients.
Towa 2B.
Worldwide.
We operate worldwide, being present in more than 40 countries.
We collaborate with the world’s leading partners to develop high-value therapeutic solutions that contribute to people’s health. Our business also includes a CMO/CDMO line, maximizing the potential of our partners’ production capabilities to deliver excellence at every stage of the process.
Our presence
Towa International’s headquarters are located in Barcelona, where we have a production facility, an R&D center, a pilot plant, corporate services, and a sales team. We also have a direct presence in Italy, Portugal, and the United States. From these locations, and through strategic alliances, we reach patients in over 40 countries.
Communication
